The Experts below are selected from a list of 65772 Experts worldwide ranked by ideXlab platform
J. Garza-flores - One of the best experts on this subject based on the ideXlab platform.
-
Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg).
Contraception, 2011Co-Authors: José Alfredo Sierra-ramírez, Roger Lara-ricalde, Miguel Lujan, Norma Velázquez-ramírez, Marycarmen Godínez-victoria, Ivonne Araceli Hernádez-munguía, Agustin Padilla, J. Garza-floresAbstract:Abstract Background The efficacy of contraceptives is affected by its route and ease of administration. Herein, both pharmacokinetics and pharmacodynamics of the once-a-month combined injectable contraceptive medroxyprogesterone acetate (MPA) plus estradiol cypionate (E 2 -Cyp) were compared after intramuscular (IM) or subcutaneous (SC) injection in women of reproductive age. Study Design Thirty women were randomly assigned to the SC ( n =15) or IM ( n =15) route of MPA 25 mg+E 2 -Cyp 5 mg administration. Serum samples were obtained daily for 7 days and then three times a week for 40 days in order to quantify E 2 , progesterone and MPA. In addition, three ultrasounds were performed on each subject to determine follicular development, and a daily record of the bleeding pattern and side effects was maintained. Results A comparative analysis showed that the main pharmacokinetic (peak serum concentration, peak serum time, area under the serum concentration vs. time curve, Absorption Half-Life and elimination Half-Life) and pharmacodynamic parameters, such as follicular development and ovulation, were similar in the SC vs. IM groups. Complete suppression in ovarian function was present in all women. The bleeding patterns and side effects were similar in both groups. Conclusions The results presented herein demonstrate that the injection of 25 mg of MPA plus 5 mg of E 2 -Cyp has similar efficacy and safety with either the SC or IM route of administration. The SC option can be considered a viable self-administered contraceptive option that might increase women's compliance to contraceptive use.
-
Original research article Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg)
2011Co-Authors: José Alfredo Sierra-ramírez, Roger Lara-ricalde, Miguel Lujan, Norma Velázquez-ramírez, Marycarmen Godínez-victoria, Ivonne Araceli Hernádez-munguía, Agustin Padilla, J. Garza-floresAbstract:Background: The efficacy of contraceptives is affected by its route and ease of administration. Herein, both pharmacokinetics and pharmacodynamics of the once-a-month combined injectable contraceptive medroxyprogesterone acetate (MPA) plus estradiol cypionate (E2-Cyp) were compared after intramuscular (IM) or subcutaneous (SC) injection in women of reproductive age. Study Design: Thirty women were randomly assigned to the SC (n=15) or IM (n=15) route of MPA 25 mg+E2-Cyp 5 mg administration. Serum samples were obtained daily for 7 days and then three times a week for 40 days in order to quantify E2, progesterone and MPA. In addition, three ultrasounds were performed on each subject to determine follicular development, and a daily record of the bleeding pattern and side effects was maintained. Results: A comparative analysis showed that the main pharmacokinetic (peak serum concentration, peak serum time, area under the serum concentration vs. time curve, Absorption Half-Life and elimination Half-Life) and pharmacodynamic parameters, such as follicular development and ovulation, were similar in the SC vs. IM groups. Complete suppression in ovarian function was present in all women. The bleeding patterns and side effects were similar in both groups. Conclusions: The results presented herein demonstrate that the injection of 25 mg of MPA plus 5 mg of E2-Cyp has similar efficacy and safety with either the SC or IM route of administration. The SC option can be considered a viable self-administered contraceptive option that might increase women's compliance to contraceptive use.
Mouangue Nanimina Alexis - One of the best experts on this subject based on the ideXlab platform.
-
a pharmacokinetic study of flumequine in sea bass dicentrarchus labrax l after a single intravascular injection
Journal of Fish Diseases, 2002Co-Authors: George Rigos, A E Tyrpenou, I Nengas, Mouangue Nanimina AlexisAbstract:The pharmacokinetic properties of flumequine following a single intravascular injection (10 mg kg - 1 fish) were studied in sea bass, Dicentrarchus labrax (L.), 120 g held at 18 °C. The Absorption half life (t 1 / 2 α ) and the elimination half life (t 1 / 2 β ) of the drug were calculated to be 1.05 and 10.71 h, respectively. Tissue penetration of flumequine seemed to be moderate because both the apparent volume of distribution of the drug at steady-state (V d ( s s ) ) and the extensive apparent volume of the central compartment (V c ) were found to be small (1.51 and 0.626 L kg - 1 ). The mean residence time (MRT) was short (09.73 h) and the total clearance (CL T ) of the drug was rapid (0.156 L kg - 1 h - 1 ).
José Alfredo Sierra-ramírez - One of the best experts on this subject based on the ideXlab platform.
-
Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg).
Contraception, 2011Co-Authors: José Alfredo Sierra-ramírez, Roger Lara-ricalde, Miguel Lujan, Norma Velázquez-ramírez, Marycarmen Godínez-victoria, Ivonne Araceli Hernádez-munguía, Agustin Padilla, J. Garza-floresAbstract:Abstract Background The efficacy of contraceptives is affected by its route and ease of administration. Herein, both pharmacokinetics and pharmacodynamics of the once-a-month combined injectable contraceptive medroxyprogesterone acetate (MPA) plus estradiol cypionate (E 2 -Cyp) were compared after intramuscular (IM) or subcutaneous (SC) injection in women of reproductive age. Study Design Thirty women were randomly assigned to the SC ( n =15) or IM ( n =15) route of MPA 25 mg+E 2 -Cyp 5 mg administration. Serum samples were obtained daily for 7 days and then three times a week for 40 days in order to quantify E 2 , progesterone and MPA. In addition, three ultrasounds were performed on each subject to determine follicular development, and a daily record of the bleeding pattern and side effects was maintained. Results A comparative analysis showed that the main pharmacokinetic (peak serum concentration, peak serum time, area under the serum concentration vs. time curve, Absorption Half-Life and elimination Half-Life) and pharmacodynamic parameters, such as follicular development and ovulation, were similar in the SC vs. IM groups. Complete suppression in ovarian function was present in all women. The bleeding patterns and side effects were similar in both groups. Conclusions The results presented herein demonstrate that the injection of 25 mg of MPA plus 5 mg of E 2 -Cyp has similar efficacy and safety with either the SC or IM route of administration. The SC option can be considered a viable self-administered contraceptive option that might increase women's compliance to contraceptive use.
-
Original research article Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg)
2011Co-Authors: José Alfredo Sierra-ramírez, Roger Lara-ricalde, Miguel Lujan, Norma Velázquez-ramírez, Marycarmen Godínez-victoria, Ivonne Araceli Hernádez-munguía, Agustin Padilla, J. Garza-floresAbstract:Background: The efficacy of contraceptives is affected by its route and ease of administration. Herein, both pharmacokinetics and pharmacodynamics of the once-a-month combined injectable contraceptive medroxyprogesterone acetate (MPA) plus estradiol cypionate (E2-Cyp) were compared after intramuscular (IM) or subcutaneous (SC) injection in women of reproductive age. Study Design: Thirty women were randomly assigned to the SC (n=15) or IM (n=15) route of MPA 25 mg+E2-Cyp 5 mg administration. Serum samples were obtained daily for 7 days and then three times a week for 40 days in order to quantify E2, progesterone and MPA. In addition, three ultrasounds were performed on each subject to determine follicular development, and a daily record of the bleeding pattern and side effects was maintained. Results: A comparative analysis showed that the main pharmacokinetic (peak serum concentration, peak serum time, area under the serum concentration vs. time curve, Absorption Half-Life and elimination Half-Life) and pharmacodynamic parameters, such as follicular development and ovulation, were similar in the SC vs. IM groups. Complete suppression in ovarian function was present in all women. The bleeding patterns and side effects were similar in both groups. Conclusions: The results presented herein demonstrate that the injection of 25 mg of MPA plus 5 mg of E2-Cyp has similar efficacy and safety with either the SC or IM route of administration. The SC option can be considered a viable self-administered contraceptive option that might increase women's compliance to contraceptive use.
George Rigos - One of the best experts on this subject based on the ideXlab platform.
-
a pharmacokinetic study of flumequine in sea bass dicentrarchus labrax l after a single intravascular injection
Journal of Fish Diseases, 2002Co-Authors: George Rigos, A E Tyrpenou, I Nengas, Mouangue Nanimina AlexisAbstract:The pharmacokinetic properties of flumequine following a single intravascular injection (10 mg kg - 1 fish) were studied in sea bass, Dicentrarchus labrax (L.), 120 g held at 18 °C. The Absorption half life (t 1 / 2 α ) and the elimination half life (t 1 / 2 β ) of the drug were calculated to be 1.05 and 10.71 h, respectively. Tissue penetration of flumequine seemed to be moderate because both the apparent volume of distribution of the drug at steady-state (V d ( s s ) ) and the extensive apparent volume of the central compartment (V c ) were found to be small (1.51 and 0.626 L kg - 1 ). The mean residence time (MRT) was short (09.73 h) and the total clearance (CL T ) of the drug was rapid (0.156 L kg - 1 h - 1 ).
Laurens Manning - One of the best experts on this subject based on the ideXlab platform.
-
subcutaneous administration of benzathine benzylpenicillin g has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection a randomized crossover population pharmacokinetic study in
Journal of Antimicrobial Chemotherapy, 2020Co-Authors: Joseph Kado, Jonathan R Carapetis, Sam Salman, Robert Henderson, Robert Hand, Rosemary Wyber, Madhu Pagesharp, Kevin T Batty, Laurens ManningAbstract:BACKGROUND Benzathine penicillin G has been used as monthly deep intramuscular (IM) injections since the 1950s for secondary prevention of acute rheumatic fever and rheumatic heart disease (RHD). Injection frequency and pain are major programmatic barriers for adherence, prompting calls for development of better long-acting penicillin preparations to prevent RHD. We hypothesized that subcutaneous (SC) administration of benzathine penicillin G could delay penicillin Absorption when compared with IM injections. METHODS To compare the pharmacokinetic profile and tolerability of benzathine penicillin G according to different routes of administration, 15 healthy males participated in a randomized crossover study to receive benzathine penicillin G by either SC or IM routes, with a 10 week washout period before the second dose by the alternative route. Ultrasound guidance confirmed injection location. Penicillin concentrations and pain scores were measured for 6 weeks following injections. RESULTS SC administration was well tolerated with no significant differences in pain scores. Following SC injection, the principal Absorption Half-Life (95% CI) was 20.1 (16.3-29.5) days and 89.6% (87.1%-92.0%) of the drug was directed via this pathway compared with 10.2 (8.6-12.5) days and 71.3% (64.9%-77.4%) following IM administration. Lower peak and higher trough penicillin concentrations resulted following SC injection. Simulations demonstrated that SC infusion of higher doses of benzathine penicillin G could provide therapeutic penicillin concentrations for 3 months. CONCLUSIONS SC administration of benzathine penicillin G is safe and significantly delays penicillin Absorption. High-dose benzathine penicillin G via the SC route would fulfil many product characteristics required for the next generation of longer-acting penicillins for use in RHD.
